Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.46 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14678382 | 0.87 | HPGD (0.54) | TSHRHTTALDH1A1HPGDMEN1 | |
| SCHEMBL28303418 | 0.87 | MEN1 (0.49) | TSHRHTTALDH1A1HPGDMEN1 | |
| SCHEMBL14874304 | 0.86 | HPGD (0.50) | TSHRHTTALDH1A1HPGDMEN1 | |
| SCHEMBL2673221 | 0.86 | ALDH1A1 (0.49) | TSHRHTTALDH1A1HPGDMEN1 | |
| SCHEMBL14874617 | 0.85 | TSHR (0.50) | TSHRHTTALDH1A1HPGDMAPT | |
| SCHEMBL18050420 | 0.85 | EPHX2 (0.42) | TSHRMEN1KMT2AEPHX2PPARG | |
| SCHEMBL14874453 | 0.85 | TSHR (0.46) | TSHRHTTALDH1A1HPGDMEN1 | |
| SCHEMBL18342037 | 0.84 | CYP1A2 (0.48) | TSHRHTTALDH1A1HPGDMEN1 | |
| SCHEMBL28582434 | 0.84 | CYP1A2 (0.48) | TSHRHTTALDH1A1HPGDMEN1 | |
| SCHEMBL28584327 | 0.84 | CYP1A2 (0.48) | TSHRHTTALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2316846-B1 | Spatially-defined macrocyclic compounds useful for drug discovery | OCERA THERAPEUTICS INC (US) | 2019-10-02 | — | — | EP | disclosed |
| US-10258602-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-9949949-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9949949-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-2768873-B1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE ITALIA SRL (IT) | 2017-11-22 | — | — | EP | disclosed |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2017-02-16 | — | — | US | disclosed |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2017-02-16 | — | — | US | disclosed |
| EP-2118080-B1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | OCERA THERAPEUTICS INC (US) | 2016-08-31 | — | — | EP | disclosed |
| CN-104254551-B | Catalyst components for the polymerization of olefins | 巴塞尔聚烯烃意大利有限公司 | 2016-08-17 | — | — | CN | disclosed |
| US-9371297-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-8440851-B2 | Spatially-defined macrocyclic compounds useful for drug discovery | TRANZYME PHARMA, INC. (CA) | 2013-05-14 | — | — | US | disclosed |
| WO-2013057026-A2 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2013-04-25 | — | — | WO | disclosed |
| EP-2583985-A1 | Catalyst components for the polymerization of olefins | Basell Poliolefine Italia S.r.l. (IT) | 2013-04-24 | — | — | EP | disclosed |
| EP-2431380-A2 | Macrocyclic antagonist of the motilin receptor for treatment of gastrointestinal dysmotility disorders | Tranzyme Pharma, Inc. (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20110237785-A1 | SPATIALLY-DEFINED MACROCYCLIC COMPOUNDS USEFUL FOR DRUG DISCOVERY | MALLINCKRODT CARRIBEAN, INC. | 2011-09-29 | — | — | US | disclosed |
| US-20100093720-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED (IE) | 2010-04-15 | — | — | US | disclosed |
| EP-2054429-A2 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | Tranzyme Pharma, Inc. (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008033328-A2 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | TRANZYME PHARMA, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093720-A1 | MACROCYCLIC ANTAGONISTS OF THE MOTILIN RECEPTOR FOR TREATMENT OF GASTROINTESTINAL DYSMOTILITY DISORDERS | MLNR, GIPR, GPR39 | TSHR 37/4885HTT 1828/4885ALDH1A1 4480/4885 |
| US-10258602-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | GHSR, GHRHR, GIPR | TSHR 64/4885HTT 361/4885ALDH1A1 4297/4885 |
| US-20110237785-A1 | SPATIALLY-DEFINED MACROCYCLIC COMPOUNDS USEFUL FOR DRUG DISCOVERY | MLNR, GIPR, CCKAR | TSHR 83/4885HTT 584/4885ALDH1A1 4496/4885 |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | TSHR 72/4885HTT 417/4885ALDH1A1 4245/4885 |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | TSHR 64/4885HTT 361/4885ALDH1A1 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.